Synairgen Reports Topline Data From ACTIV-2 Phase 2 Trial For SNG001 - Quick Facts

Synairgen plc (SNG.L) reported topline data for participants treated with SNG001 in the US National Institutes of Health/AIDS Clinical Trials Group-led ACTIV-2 phase 2 adaptive platform trial in home-based participants with COVID-19. In the study, there were no statistically significant differences between SNG001 and placebo with respect to the primary outcomes of safety, symptom resolution, or virology. The company said fewer participants required hospitalisation following treatment with SNG001 compared to placebo, which was not statistically significant.

Synairgen noted that, full results including other key endpoints, will be presented and/or published by the NIH in due course.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Foxconn, Apple Inc.'s key iPhone assembler, expects that its major plant in China, which is being hit hard by worker unrest following Covid-19 spread and related restrictions, would restart full production around late December to early January, Reuters reported citing a Foxconn source. Nestle Purina PetCare Co. has recalled a limited amount of certain prescription wet dog food citing labeling error, the U.S. Food and Drug Administration said. The recall involves Purina Pro Plan Veterinary Diets EN Gastroenteric Low Fat or PPVD EN Low Fat wet dog food that comes in 13.4 oz cans. Exportadora Copramar is recalling 1260 cases of James Farm frozen raspberries citing potential to be contaminated with Hepatitis A, the U.S. Food and Drug Administration said. The recall involves James Farm branded frozen raspberries identified by UPC Code: 76069501010 and Lot Code - 22-165.
Follow RTT